A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age

Journal article published in Vaccine and co-authored by PATH's Yuxiao Tang, Renee Holt, and Bruce Innis.

Publication date: November 2022

A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age

View Resource